Matt O'Brien
Stock Analyst at Piper Sandler
(2.17)
# 2,773
Out of 4,944 analysts
183
Total ratings
41.72%
Success rate
-6.16%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $80 → $55 | $40.38 | +36.21% | 4 | Aug 7, 2025 | |
| TNDM Tandem Diabetes Care | Downgrades: Neutral | $30 → $14 | $11.13 | +25.79% | 9 | Aug 7, 2025 | |
| DXCM DexCom | Maintains: Overweight | $90 → $100 | $79.96 | +25.06% | 12 | Jul 31, 2025 | |
| CNMD CONMED | Maintains: Overweight | $80 → $68 | $55.19 | +23.21% | 13 | Jul 31, 2025 | |
| TMDX TransMedics Group | Reiterates: Overweight | $125 → $145 | $132.04 | +9.82% | 12 | Jun 4, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $100 → $80 | $62.79 | +27.41% | 12 | May 9, 2025 | |
| CVRX CVRx, Inc. | Maintains: Overweight | $20 → $12 | $7.73 | +55.24% | 9 | May 9, 2025 | |
| KIDS OrthoPediatrics | Maintains: Overweight | $40 → $30 | $20.09 | +49.33% | 2 | May 8, 2025 | |
| ATEC Alphatec Holdings | Reiterates: Overweight | $13 → $15 | $15.80 | -5.06% | 3 | May 2, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $180 → $165 | $91.79 | +79.76% | 10 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $15.89 | +69.92% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 → $2 | $1.47 | +36.52% | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $4.25 | -17.65% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $122.92 | +13.90% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $15.10 | +72.19% | 1 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $308.68 | +0.43% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $257.38 | +28.22% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $36.73 | +36.13% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $28.21 | -43.28% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $102.50 | +12.20% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $5.76 | +108.33% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $378.95 | +10.83% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 → $140 | $109.58 | +27.76% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $92.91 | -3.13% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $15.70 | +59.24% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $1.78 | +68.54% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $2.36 | +90.68% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $103.22 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $2.66 | +463.91% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $74.27 | +46.43% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $1.65 | +1,001.82% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $24.11 | +231.81% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $4.30 | +179.07% | 1 | Jun 24, 2020 |
PROCEPT BioRobotics
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $55
Current: $40.38
Upside: +36.21%
Tandem Diabetes Care
Aug 7, 2025
Downgrades: Neutral
Price Target: $30 → $14
Current: $11.13
Upside: +25.79%
DexCom
Jul 31, 2025
Maintains: Overweight
Price Target: $90 → $100
Current: $79.96
Upside: +25.06%
CONMED
Jul 31, 2025
Maintains: Overweight
Price Target: $80 → $68
Current: $55.19
Upside: +23.21%
TransMedics Group
Jun 4, 2025
Reiterates: Overweight
Price Target: $125 → $145
Current: $132.04
Upside: +9.82%
Globus Medical
May 9, 2025
Maintains: Overweight
Price Target: $100 → $80
Current: $62.79
Upside: +27.41%
CVRx, Inc.
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $7.73
Upside: +55.24%
OrthoPediatrics
May 8, 2025
Maintains: Overweight
Price Target: $40 → $30
Current: $20.09
Upside: +49.33%
Alphatec Holdings
May 2, 2025
Reiterates: Overweight
Price Target: $13 → $15
Current: $15.80
Upside: -5.06%
Glaukos
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $91.79
Upside: +79.76%
Mar 31, 2025
Initiates: Overweight
Price Target: $27
Current: $15.89
Upside: +69.92%
Mar 21, 2025
Downgrades: Neutral
Price Target: $5 → $2
Current: $1.47
Upside: +36.52%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $4.25
Upside: -17.65%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $122.92
Upside: +13.90%
Feb 24, 2025
Initiates: Overweight
Price Target: $26
Current: $15.10
Upside: +72.19%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $308.68
Upside: +0.43%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $257.38
Upside: +28.22%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $36.73
Upside: +36.13%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $28.21
Upside: -43.28%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $102.50
Upside: +12.20%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $5.76
Upside: +108.33%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $378.95
Upside: +10.83%
Oct 25, 2024
Reiterates: Overweight
Price Target: $125 → $140
Current: $109.58
Upside: +27.76%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $92.91
Upside: -3.13%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $15.70
Upside: +59.24%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $1.78
Upside: +68.54%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $2.36
Upside: +90.68%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $103.22
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $2.66
Upside: +463.91%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $74.27
Upside: +46.43%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $1.65
Upside: +1,001.82%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $24.11
Upside: +231.81%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $4.30
Upside: +179.07%